Pills masthead

News Releases

Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014

201320122011201020092008200720062004

2023 Archives

May 2, 2023

Restructuring Support Agreement Supported by Holders of More than 80% of the Company's Senior Secured Notes and 100% of Holders of Second Lien Term Loan Restructuring Transactions Will Reduce the...

More
May 1, 2023

Restructuring Support Agreement Supported by Holders of More Than 80% of the Company's Senior Secured Notes and 100% of the Company's Second Lien Term Loans Transaction Will Significantly...

More
Apr 20, 2023

Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett...

More
Apr 4, 2023

Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet...

More
Feb 1, 2023

Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two...

More
Jan 25, 2023

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m....

More
Jan 25, 2023

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett...

More
Jan 4, 2023

--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLogĀ®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed,...

More
 
Price Data
NYSELCI